Metabolism of CP-195,543, a leukotriene B4 receptor antagonist, in the Long-Evans rat and Cynomolgus monkey.
1. The fate of [14C]CP-195,543, a novel leukotriene B4 receptor antagonist, was studied following oral administration to the Long-Evans rat and Cynomolgus monkey. 2. Most of the radioactivity was primarily excreted in the faeces, and urine was a minor route of excretion. 3. CP-195,543 was extensively metabolized in the two species, primarily by two metabolic pathways: glucuronidation of unchanged CP-195,543 and oxidative metabolism, presumably by cytochrome P450. 4. The sites of glucuronidation were the carboxylic acid moiety and the hydroxy group. The ester glucuronide was the predominant glucuronide conjugate detected in the rat, whereas the monkey generated the ether as well as the ester glucuronide. 5. The structures of oxidative metabolites were elucidated using mass spectrometry (in the positive- and negative-ion mode) and 1H-NMR. The sites of hydroxylation were the benzylic group and the 3-position of the benzopyran ring. 6. This study has indicated that CP-195,543 was mainly eliminated by Phase II metabolism in both species.
Dalvie
D K
DK
Candidate Synthesis, Enhancement and Evaluation, Pfizer Central Research, Groton, CT 06340, USA. deepak_k_dalvie@groton.pfizer.com
O'Donnell
J P
JP
D000818:Animals; D001646:Bile / Q000378:metabolism; D001711:Biotransformation; D002839:Chromans / Q000378:metabolism* / Q000493:pharmacokinetics; D002851:Chromatography, High Pressure Liquid; D005243:Feces / Q000737:chemistry; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D020024:Leukotriene Antagonists / Q000378:metabolism* / Q000493:pharmacokinetics; D008252:Macaca fascicularis; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D051381:Rats; D020318:Rats, Long-Evans; D018102:Receptors, Leukotriene B4 / Q000037:antagonists & inhibitors*; D013045:Species Specificity
D002839:Chromans; D020024:Leukotriene Antagonists; D018102:Receptors, Leukotriene B4; C112776:CP 195543